Category: Side Effect: Cardiovascular (heart attack, stroke, heart failure, PE, DVT)
-
Lemtrada Use Restrictions Issued By EMA’s Pharmacovigilance Risk Assessment Committee Due To Safety Issues
Action Due To Reports Of Lemtrada Side Effects Including Deaths Related To Immune Complications And Heart Or Circulatory Disorders (Posted by Tom Lamb at DrugInjuryWatch.com) In late October 2019 the Pharmacovigilance Risk…
-
European Medicines Agency (EMA) Warns Xeljanz Increases Risk Of Pulmonary Embolism (PE) And Deep Vein Thrombosis (DVT)
Recommends That Xeljanz Should Be Used With Caution In Patients At High Risk Of Blood Clots As Well Aa In Patients Older Than 65 Years Of Age (Posted by Tom Lamb at DrugInjuryWatch.com)…
-
Xeljanz Warning For Increased Risk Of Blood Clots And Death With Higher Dose Used For Ulcerative Colitis
"Black Box Warning" For Xeljanz 10 mg Twice Daily Dose Required By FDA In July 2019 Follows Regulatory Action In Europe (Posted by Tom Lamb at DrugInjuryWatch.com) A Xeljanz FDA Drug Safety…
-
Uloric Use By Patients With Major Cardiovascular Disease Associated With Higher Risk Of Deaths
New Drug Safety Warning: Uloric Should Be Avoided When There Is Prior Myocardial Infarction, Stroke, Or Unstable Angina (Posted by Tom Lamb at DrugInjuryWatch.com) From this Drug Safety Update issued July 17,…
-
Lemtrada: Reports Of Serious Cardiovascular Events And Immune-Mediated Reactions Under Investigation
UK Drug Safety Regulator MHRA Imposes Lemtrada Use Restrictions And Mandates Patient Monitoring For Side Effects (Posted by Tom Lamb at DrugInjuryWatch.com) In May 2019 the UK's Medicines and Healthcare products Regulatory…
-
Xeljanz Related Blood Clots Can Cause Pulmonary Embolism (PE) Or Deep Vein Thrombosis (DVT) With Patient Deaths Possible
Serious Side Effects For Xeljanz 10 mg Dose Found In Pfizer Post-Marketing Study Leads To New European Drug Safety Regulatory Action (Posted by Tom Lamb at DrugInjuryWatch.com) The serious side effects associated…
-
Uloric Lawsuits Involving Heart Attacks And Strokes Follow Recent FDA Warnings About Cardiovascular Deaths
February 2019 Uloric Label Changes Include New "Black-Box Warning" To The Effect That Uloric Is Gout Drug Of Last Resort (Posted by Tom Lamb at DrugInjuryWatch.com) As a result of recent FDA-mandated…
-
Lemtrada Review By European Drug Regulatory Agency Covers Various Serious Side Effects In MS Patients
EMA Will Investigate Reports Of Associated Conditions Beyond Those That Were In November 2018 FDA Drug Safety Communication (Posted by Tom Lamb at DrugInjuryWatch.com) We recently learned by means of this April…
-
Zelnorm Approved By FDA (Again) In 2019 – Despite Zelnorm Being Removed From Market In 2007 For Safety Concerns
Concerns About Potential Cardiovascular Safety Signal As Well As Suicidal Ideation And Behavior Were Involved With Zelnorm Recall (Posted by Tom Lamb at DrugInjuryWatch.com) In October 2018 we wrote this article, “Waiting…